Bioventix PLC - London-based biotechnology company - Pretax profit totals GBP8.1 million in the year ended June 30, down slightly from GBP8.2 million the year prior but up 16% from the GBP7.0 million reported two years earlier. Revenue rises to GBP10.9 million, up 6.0% year-on-year from GBP10.3 million and 18% above the GBP9.3 million taken in financial 2019. Dividend totals 105 pence, up 19% from 88p in financial 2020. Total dividend includes two interim dividends of 62p and 43p respectively.
"The core business is linked to routine testing at hospitals around the world and this has undoubtedly been affected by the Covid-19 pandemic. The timing of a return to normality is uncertain but when it does, we expect our business will revert to an established trajectory, albeit without the income from NT-proBNP which ceased from July 2021. Regardless of the pandemic effects, we anticipate the continued roll-out of the high sensitivity troponin assays and the royalties associated with this," the company says.
Current stock price: 3,900.00p
Year-to-date change: down 11%
By Scarlett Butler; scarlettbutler@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Bioventix (BVXP)